Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+3.67%
+1.24%
-5.00%
+24.42%
SLNO
Soleno Therapeutics Inc.
$75.51
Chart
$73.26 (+3.07%)
$49.03 (+54.01%)
$49.36 (+52.98%)
$41.15 (+83.50%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.67%
+1.24%
-5.00%
+24.42%
SLNO
Soleno Therapeutics Inc.
Current Price
$75.51
Login to view Soleno Therapeutics Inc. (SLNO) recommendation from the last 90 days from financial news and social media.
Chart
$73.26 (+3.07%)
$49.03 (+54.01%)
$49.36 (+52.98%)
$41.15 (+83.50%)
SLNO Latest Headlines
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome. REDWOOD CITY Calif. May 22 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics Inc. (Soleno) (NASDAQ: SLNO) a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases today announced that Solenos Marketing Authorization Application (MAA) seeking regulat
Thu May 22, 2025
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome. REDWOOD CITY Calif. May 22 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics Inc. (Soleno) (NASDAQ: SLNO) a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases today announced that Solenos Marketing Authorization Application (MAA) seeking regulat
Thu May 22, 2025
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome. REDWOOD CITY Calif. May 20 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics Inc. (NASDAQ:) a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases today announced data presented from its clinical dev
Tue May 20, 2025
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome. REDWOOD CITY Calif. May 20 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics Inc. (NASDAQ:) a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases today announced data presented from its clinical dev
Tue May 20, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SLNO Stock trends
SLNO Stock performance
SLNO Stock analysis
SLNO investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
